Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMAC opposes recommended label comprehension trials to support switches in Canada.

This article was originally published in The Tan Sheet

Executive Summary

OTC SWITCH MANDATORY LABEL COMPREHENSION STUDIES "PREMATURE" IN CANADA, the Nonprescription Drug Manufacturers Association of Canada said in June 28 comments submitted to the Drugs Directorate. The comments respond to specific points made in a final report on the Rx-to-OTC switch process in Canada, prepared for the Bureau of Pharmaceutical Assessment by Panacea Consulting ("The Tan Sheet" May 27, p. 13).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085569

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel